Capricor Therapeutics, Inc. $CAPR Shares Purchased by Woodline Partners LP

Key Points

• Woodline Partners LP increased its stake in Capricor Therapeutics by 15.8% in Q1, owning 1.60% of the company valued at approximately $6.9 million.
• Capricor's stock has experienced significant volatility, with a 1-year range between $4.20 and $23.40, and currently opened at $6.36 with a market cap of $290.78 million.
• Recent analyst ratings on Capricor Therapeutics show a mix of sentiments, with target prices ranging from $12.00 to $40.00, indicating differing expectations for the stock's future performance.

Woodline Partners LP boosted its stake in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 15.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 729,318 shares of the biotechnology company's stock after buying an additional 99,384 shares during the quarter. Woodline Partners LP owned 1.60% of Capricor Therapeutics worth $6,921,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CAPR. Octagon Capital Advisors LP acquired a new position in Capricor Therapeutics during the first quarter worth about $4,270,000. Jump Financial LLC acquired a new position in Capricor Therapeutics during the first quarter worth about $1,547,000. Bank of America Corp DE grew its position in Capricor Therapeutics by 938.9% during the fourth quarter. Bank of America Corp DE now owns 170,543 shares of the biotechnology company's stock worth $2,353,000 after buying an additional 154,127 shares during the period. Nuveen Asset Management LLC grew its position in Capricor Therapeutics by 392.7% during the fourth quarter. Nuveen Asset Management LLC now owns 169,111 shares of the biotechnology company's stock worth $2,334,000 after buying an additional 134,791 shares during the period. Finally, Rafferty Asset Management LLC acquired a new position in Capricor Therapeutics during the fourth quarter worth about $1,743,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Stock Performance

Shares of CAPR opened at $6.36 on Friday. The company has a market capitalization of $290.78 million, a price-to-earnings ratio of -3.88 and a beta of 0.73. The company's 50 day simple moving average is $7.39 and its 200 day simple moving average is $9.84. Capricor Therapeutics, Inc. has a 1 year low of $4.20 and a 1 year high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%. Equities analysts expect that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on CAPR shares. Jones Trading lowered their target price on shares of Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating on the stock in a research report on Wednesday, June 25th. Wall Street Zen downgraded shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $24.00 price target on shares of Capricor Therapeutics in a report on Thursday. Piper Sandler reaffirmed an "overweight" rating and issued a $20.00 price target on shares of Capricor Therapeutics in a report on Friday, July 11th. Finally, Roth Capital reduced their price target on shares of Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating on the stock in a report on Monday, July 14th. One investment analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $22.56.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Want to see what other hedge funds are holding CAPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.